DR. DOUGLAS K. ROVIRA, M.D.

CHICAGO, IL

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 10 publications 1990 – 2025 NPI: 1598767733
Randomized Controlled Trials as TopicDrug Therapy, CombinationFeasibility StudiesHIV InfectionsAnti-HIV AgentsSpainPatient SatisfactionPyridonesDiketopiperazinesRilpivirinePolymersMulticenter Studies as TopicClinical Trials, Phase IV as TopicElectronsZinc Oxide

Practice Location

5841 S MARYLAND AVE
CHICAGO, IL 60637-1443

Phone: (888) 824-0200

What does DOUGLAS ROVIRA research?

Dr. Rovira studies advanced materials that can be used in renewable energy solutions, especially in solar panels and energy conversion systems. His research involves creating and testing new compounds, such as pnictogen chalcohalides and other tuneable materials, which have desirable properties for efficient energy usage. In addition, he investigates improved treatment methods for conditions like HIV, exploring how long-acting therapies can be administered outside of hospital settings. His studies also cover the impacts of different treatments on cancer patients, aiming to enhance both the effectiveness and safety of chemotherapy.

Key findings

  • In the development of Bi(SSe)(IBr) materials, modifications led to high-quality films that can be utilized in sustainable energy applications.
  • The pnictogen chalcohalides exhibited a bandgap of 1.2 to 2.2 eV and high stability, positioning them as promising candidates for next-generation energy devices.
  • In the HOLA study, patients receiving the long-acting HIV therapy outside of the hospital reported improved satisfaction and feasibility compared to traditional methods.
  • Switching to a polymer interlayer in solar cells resulted in an increase in open-circuit voltage from 243 millivolts to 344 millivolts, achieving a maximum efficiency of 2.4%.
  • The study on doxorubicin showed that patients taking liposome-encapsulated doxorubicin had a 16% lower incidence of heart-related side effects compared to those on conventional doxorubicin.

Frequently asked questions

Does Dr. Rovira study sustainable energy materials?
Yes, Dr. Rovira specifically researches new materials that can be used in renewable energy technologies like solar panels.
What treatments has Dr. Rovira explored for HIV?
He has investigated the administration of long-acting therapies for HIV outside of hospitals to improve accessibility and patient satisfaction.
Is Dr. Rovira's work relevant to cancer patients?
Yes, he has studied safer chemotherapy options for patients with conditions like metastatic breast cancer, focusing on reducing heart-related side effects.
How does agriculture affect freshwater ecosystems according to Dr. Rovira's research?
His studies indicate that increased agriculture can harm stream health and disrupt natural decomposition processes vital for the environment.
Are there any findings about the effects of pesticides on freshwater species?
Yes, his research found that certain invertebrates in tropical streams can suffer up to 50% mortality from pesticide exposure, highlighting environmental risks.

Publications in plain English

Exploring the acceptability, appropriateness, feasibility and satisfaction of an implementation strategy for out-of-HOspital administration of the Long-Acting combination of cabotegravir and rilpivirine as an optional therapy for HIV in Spain (the HOLA study)-a hybrid implementation-effectiveness, phase IV, double-arm, open-label, multicentric study: study protocol.

2025

BMJ open

Negredo E, Hernández-Sánchez D, Álvarez-López P, Falcó V, Rivero À +15 more

Plain English
The HOLA study is testing a new way to provide a long-acting HIV treatment called cabotegravir and rilpivirine (CAB+RPV) outside of hospitals in Spain. It involves 110 people living with HIV, some already taking this treatment, and compares their experiences and safety between receiving this therapy in hospital versus in outpatient settings like community centers or clinics. The results could change how HIV care is delivered, making it more accessible and convenient for patients. Who this helps: This helps patients living with HIV by offering them more treatment options and potentially improving their quality of life.

PubMed

Ribbons of Light: Emerging (Sb,Bi)(S,Se)(Br,I) Van der Waals Chalcohalides for Next-Generation Energy Applications.

2025

Small (Weinheim an der Bergstrasse, Germany)

Caño I, Navarro-Güell A, Maggi E, Gon Medaille A, Rovira D +22 more

Plain English
This study examines a new group of materials called pnictogen chalcohalides, which show promise for use in energy technologies like solar panels and energy conversion systems. Researchers developed a new way to create these materials and found they have a wide range of useful properties, such as a bandgap of 1.2 to 2.2 eV and high stability, making them strong candidates for efficient and sustainable energy devices. This matters because it could lead to better and more environmentally friendly energy solutions. Who this helps: This helps energy researchers and engineers looking for new materials to improve renewable energy technologies.

PubMed

Molecular Ink-Based Synthesis of Bi(SSe)(IBr) Solid Solutions as Tuneable Materials for Sustainable Energy Applications.

2025

Small methods

Rovira D, Caño I, López C, Navarro-Güell A, Asensi JM +14 more

Plain English
This study examined a new way to create materials called Bi(SSe)(IBr), which could be useful for sustainable energy applications. Researchers developed a method that allows them to control the properties of these materials, achieving high-quality films and microcrystals. Their results showed that by adjusting different components, they could modify the materials' electronic properties, which is important for technologies like solar panels and chemical sensors. Who this helps: This benefits researchers and developers in sustainable energy technologies.

PubMed

Polymeric Interlayer in CdS-Free Electron-Selective Contact for SbSeThin-Film Solar Cells.

2023

International journal of molecular sciences

Rovira D, Ros E, Tom T, Jiménez M, Miguel Asensi J +5 more

Plain English
This study looked at improving thin-film solar cells made from antimony selenide (SbSe) by replacing a harmful material called cadmium sulfide (CdS) with a new layer made of zinc oxide (ZnO) and a polymer. They found that this new setup increased the open-circuit voltage of the solar cells from 243 millivolts to 344 millivolts and achieved a maximum efficiency of 2.4%. This is important because using safer materials can make solar technology more sustainable and easier to develop for widespread use. Who this helps: This benefits both solar energy manufacturers and environmentally conscious consumers.

PubMed

High sensitivity of invertebrate detritivores from tropical streams to different pesticides.

2021

Ecotoxicology and environmental safety

Cornejo A, Encina-Montoya F, Correa-Araneda F, Rovira D, García G +7 more

Plain English
Researchers studied the effects of common pesticides on three types of tiny creatures in tropical streams that play a key role in breaking down organic matter. They found that these creatures can experience up to 50% mortality at pesticide concentrations ranging from 0.04 to 2.7 micrograms per liter, with chlorpyrifos being the most harmful. This research is important because it highlights the need to pay closer attention to the sensitivity of tropical species when assessing the risks of pesticide use on freshwater ecosystems. Who this helps: This benefits environmental scientists and conservationists working to protect freshwater habitats.

PubMed

Agriculture impairs stream ecosystem functioning in a tropical catchment.

2020

The Science of the total environment

Cornejo A, Pérez J, López-Rojo N, Tonin AM, Rovira D +11 more

Plain English
This study looked at how agriculture affects tropical streams by comparing areas with little to a lot of farming. Researchers found that as agriculture increased, microbial breakdown of plant materials sped up, but the overall decomposition slowed down because fewer small animals that help decompose, like certain insects, were found—likely due to pesticides and more sediment in the water. This is important because it shows that farming not only harms the streams’ health but could also disrupt natural processes that are vital for the environment, like nutrient recycling. Who this helps: This information is valuable for environmental policymakers and conservationists working to protect aquatic ecosystems.

PubMed

External beam radiation therapy for amyloidosis of the urinary bladder.

2018

Practical radiation oncology

Cooper CT, Greene BD, Fegan JE, Rovira D, Gertz MA +1 more

PubMed

Antiepileptic polytherapy: clinical outcome after reduction from three to two drugs. Is triple therapy justified?

2015

Acta neurologica Belgica

Hernando-Requejo V, Juárez N, Rovira D, Huertas N, Luciano Z

PubMed

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma.

2002

Cancer

Harris L, Batist G, Belt R, Rovira D, Navari R +4 more

Plain English
The study compared a new version of doxorubicin, called TLC D-99, that is encapsulated in liposomes, to conventional doxorubicin in treating metastatic breast cancer. Researchers found that 13% of patients on TLC D-99 experienced heart-related side effects, compared to 29% of those taking regular doxorubicin. Although both treatments had a similar tumor response rate of 26%, TLC D-99 caused fewer heart problems, making it a potentially safer option for patients. Who this helps: This helps breast cancer patients by offering a treatment with reduced risk of heart damage.

PubMed

Cigarette smoking, blast crisis, and survival in chronic myeloid leukemia.

1990

American journal of hematology

Herr R, Ferguson J, Myers N, Rovira D, Robinson WA

Plain English
This study looked at the impact of cigarette smoking on patients with chronic myeloid leukemia (CML). Researchers analyzed records from 122 patients and found that smokers had a shorter survival time, averaging 35 months, compared to non-smokers who lived about 47 months. Most deaths were due to a serious condition called blast crisis, with smokers surviving around 30 months after this crisis compared to 46 months for non-smokers. Who this helps: This helps patients with CML and their doctors by highlighting the risks of smoking.

PubMed

Frequent Co-Authors

Joaquim Puigdollers Edgardo Saucedo Aydeé Cornejo Francisco Correa-Araneda Gabriela García Víctor Villarreal Nicomedes Jaramillo Edgar Pérez Javier Pérez Luz Boyero

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.